FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022157561> ?p ?o ?g. }

• W2022157561 endingPage "624" @default.
• W2022157561 startingPage "621" @default.
• W2022157561 abstract "Objective GOG study 172 demonstrated improved progression-free (PFS) and overall (OS) survival for patients with stage III optimally debulked ovarian and peritoneal carcinoma treated with IV/IP paclitaxel and IP cisplatin compared to standard IV therapy. The inpatient administration, toxicity profile, and limited completion rate have been blamed for the lack of acceptance and widespread use of this regimen. We sought to evaluate the PFS, OS, toxicity, and completion rate of a modified outpatient IP regimen. Methods Using a prospectively maintained database, we evaluated the outcomes of patients who underwent primary optimal cytoreduction for stage III ovarian, tubal, or peritoneal carcinoma followed by IV/IP chemotherapy from 1/05-3/09. Our modified regimen was as follows: IV paclitaxel (135 mg/m2) over 3 h on day 1, IP cisplatin (75 mg/m2) on day 2, and IP paclitaxel (60 mg/m2) on day 8, given every 21 days for 6 cycles. Results We identified 102 patients who initiated the modified IV/IP regimen and completed chemotherapy. The median follow-up was 43 months. The median age at diagnosis was 57 years (range, 23–76). Primary disease site was: ovary, 77 (75%); fallopian tube, 13 (13%); peritoneum, 12 (12%). FIGO stage was: IIIA, 8 (8%); IIIB, 4 (4%); IIIC, 90 (88%). Residual disease after cytoreduction was: none, 58 (57%); ≤1 cm, 44 (43%). The most frequent grade 3/4 toxicities were: neutropenia, 12 (12%); gastrointestinal, 8 (8%); neurologic, 6 (6%). Eighty-two (80%) of 102 patients completed 4 or more cycles of IV/IP therapy; 56 (55%) completed all 6 cycles. The median PFS and OS were 29 and 67 months, respectively. Conclusions By modifying the GOG 172 treatment regimen, convenience, toxicity, and tolerability appear improved, with survival outcomes similar to those of GOG 172. This modified IV/IP regimen warrants further study." @default.
• W2022157561 created "2016-06-24" @default.
• W2022157561 creator A5005037311 @default.
• W2022157561 creator A5032196793 @default.
• W2022157561 creator A5040185143 @default.
• W2022157561 creator A5048186556 @default.
• W2022157561 creator A5050257316 @default.
• W2022157561 creator A5052352581 @default.
• W2022157561 creator A5054602117 @default.
• W2022157561 creator A5070891561 @default.
• W2022157561 creator A5071199136 @default.
• W2022157561 creator A5077690076 @default.
• W2022157561 creator A5090740287 @default.
• W2022157561 date "2012-06-01" @default.
• W2022157561 modified "2023-09-23" @default.
• W2022157561 title "Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer" @default.
• W2022157561 cites W1845622004 @default.
• W2022157561 cites W1922469696 @default.
• W2022157561 cites W1963078177 @default.
• W2022157561 cites W2097265582 @default.
• W2022157561 cites W2098292010 @default.
• W2022157561 cites W2107402595 @default.
• W2022157561 cites W2154175915 @default.
• W2022157561 cites W2316501478 @default.
• W2022157561 cites W4293241248 @default.
• W2022157561 doi "https://doi.org/10.1016/j.ygyno.2012.03.027" @default.
• W2022157561 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22446622" @default.
• W2022157561 hasPublicationYear "2012" @default.
• W2022157561 type Work @default.
• W2022157561 sameAs 2022157561 @default.
• W2022157561 citedByCount "42" @default.
• W2022157561 countsByYear W20221575612012 @default.
• W2022157561 countsByYear W20221575612013 @default.
• W2022157561 countsByYear W20221575612014 @default.
• W2022157561 countsByYear W20221575612015 @default.
• W2022157561 countsByYear W20221575612016 @default.
• W2022157561 countsByYear W20221575612017 @default.
• W2022157561 countsByYear W20221575612018 @default.
• W2022157561 countsByYear W20221575612019 @default.
• W2022157561 countsByYear W20221575612020 @default.
• W2022157561 countsByYear W20221575612021 @default.
• W2022157561 countsByYear W20221575612022 @default.
• W2022157561 countsByYear W20221575612023 @default.
• W2022157561 crossrefType "journal-article" @default.
• W2022157561 hasAuthorship W2022157561A5005037311 @default.
• W2022157561 hasAuthorship W2022157561A5032196793 @default.
• W2022157561 hasAuthorship W2022157561A5040185143 @default.
• W2022157561 hasAuthorship W2022157561A5048186556 @default.
• W2022157561 hasAuthorship W2022157561A5050257316 @default.
• W2022157561 hasAuthorship W2022157561A5052352581 @default.
• W2022157561 hasAuthorship W2022157561A5054602117 @default.
• W2022157561 hasAuthorship W2022157561A5070891561 @default.
• W2022157561 hasAuthorship W2022157561A5071199136 @default.
• W2022157561 hasAuthorship W2022157561A5077690076 @default.
• W2022157561 hasAuthorship W2022157561A5090740287 @default.
• W2022157561 hasConcept C121608353 @default.
• W2022157561 hasConcept C126322002 @default.
• W2022157561 hasConcept C141071460 @default.
• W2022157561 hasConcept C143998085 @default.
• W2022157561 hasConcept C2775883341 @default.
• W2022157561 hasConcept C2776694085 @default.
• W2022157561 hasConcept C2777063308 @default.
• W2022157561 hasConcept C2777249960 @default.
• W2022157561 hasConcept C2777292972 @default.
• W2022157561 hasConcept C2778239845 @default.
• W2022157561 hasConcept C2780427987 @default.
• W2022157561 hasConcept C2780435969 @default.
• W2022157561 hasConcept C2781413609 @default.
• W2022157561 hasConcept C3019054536 @default.
• W2022157561 hasConcept C71924100 @default.
• W2022157561 hasConcept C90924648 @default.
• W2022157561 hasConceptScore W2022157561C121608353 @default.
• W2022157561 hasConceptScore W2022157561C126322002 @default.
• W2022157561 hasConceptScore W2022157561C141071460 @default.
• W2022157561 hasConceptScore W2022157561C143998085 @default.
• W2022157561 hasConceptScore W2022157561C2775883341 @default.
• W2022157561 hasConceptScore W2022157561C2776694085 @default.
• W2022157561 hasConceptScore W2022157561C2777063308 @default.
• W2022157561 hasConceptScore W2022157561C2777249960 @default.
• W2022157561 hasConceptScore W2022157561C2777292972 @default.
• W2022157561 hasConceptScore W2022157561C2778239845 @default.
• W2022157561 hasConceptScore W2022157561C2780427987 @default.
• W2022157561 hasConceptScore W2022157561C2780435969 @default.
• W2022157561 hasConceptScore W2022157561C2781413609 @default.
• W2022157561 hasConceptScore W2022157561C3019054536 @default.
• W2022157561 hasConceptScore W2022157561C71924100 @default.
• W2022157561 hasConceptScore W2022157561C90924648 @default.
• W2022157561 hasIssue "3" @default.
• W2022157561 hasLocation W20221575611 @default.
• W2022157561 hasLocation W20221575612 @default.
• W2022157561 hasOpenAccess W2022157561 @default.
• W2022157561 hasPrimaryLocation W20221575611 @default.
• W2022157561 hasRelatedWork W1224191223 @default.
• W2022157561 hasRelatedWork W1993880164 @default.
• W2022157561 hasRelatedWork W2025149885 @default.
• W2022157561 hasRelatedWork W2072767112 @default.
• W2022157561 hasRelatedWork W2158478263 @default.
• W2022157561 hasRelatedWork W2320097775 @default.

• next